# US 2022/0031846 A1 · Animal protein-free pharmaceutical compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031846 A1
- Document ID: US20220031846A1
- Status: Published application
- Kind: A1
- Application number: 17/505,048
- Filed: 2021-10-19
- Published: 2022-02-03
- Earliest claimed: 2005-10-06
- Assignees: Allergan, Inc.
- Applicants: Allergan, Inc.
- Inventors: Terrence J. Hunt
- Web page: https://patentgrep.com/patent/US20220031846A1

## CPC

- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Animal protein-free, solid-form Clostridial toxin pharmaceutical compositions comprising a Clostridial toxin active ingredient and at least two excipients.

## Claims

### Claim 1

A method to stabilize a Clostridial neurotoxin, comprising:
providing an aqueous solution comprising a Clostridial neurotoxin and a non-mammalian protein excipient; and
compounding the solution with one or more additional non-protein excipients to provide a formulation comprising the neurotoxin in stable form.

### Claim 2 (depends on 1)

The method of claim 1, wherein compounding comprises adding the one or more additional non-protein excipients to water to form a solution and adding the aqueous solution thereto.

### Claim 3

A powder pharmaceutical composition, comprising:
a botulinum toxin, wherein the botulinum toxin is a type A serotype;
a surfactant;
at least one disaccharide selected from the group consisting of sucrose and trehalose; and
a buffer sufficient to maintain a pH of from about 5 to about 7.3 upon reconstitution with sterile normal saline or water;
wherein the composition is suitable for intramuscular or subcutaneous injection following reconstitution with sterile normal saline or water,
wherein the composition is animal protein free, and
wherein the composition retains at least about 75% of the theoretical maximum potency of the botulinum toxin following storage as a powder for three months at room temperature.

### Claim 4 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pharmaceutical composition is produced by lyophilization or vacuum-drying.

### Claim 5 (depends on 3)

The pharmaceutical composition of claim 3, wherein the botulinum toxin has a molecular weight of about 150 kD.

### Claim 6 (depends on 3)

The pharmaceutical composition of claim 3, wherein the surfactant is poloxamer 188.

### Claim 7 (depends on 3)

The pharmaceutical composition of claim 3, wherein the disaccharide is sucrose.

### Claim 8 (depends on 3)

The pharmaceutical composition of claim 3, wherein the buffer is citrate buffer.

### Claim 9 (depends on 3)

The pharmaceutical composition of claim 3, wherein the buffer is an amino acid buffer.

### Claim 10 (depends on 3)

The pharmaceutical composition of claim 3, wherein the room temperature is about 20° C.

### Claim 11 (depends on 3)

The pharmaceutical composition of claim 3, wherein the pH is from about 5.5 to about 6.5.

### Claim 12 (depends on 3)

The pharmaceutical composition of claim 3, wherein the disaccharide is trehalose.

### Claim 13 (depends on 3)

The pharmaceutical composition of claim 3, wherein the buffer is a phosphate buffer.

### Claim 14 (depends on 3)

The pharmaceutical composition of claim 3, wherein the disaccharide is present in an amount of about 5 mg to about 250 mg for each about 100 units of the botulinum toxin.

### Claim 15 (depends on 3)

The pharmaceutical composition of claim 3, comprising about 100 units to about 200 units of the botulinum toxin.

### Claim 16

A powder pharmaceutical composition, comprising:
a 150 kD botulinum toxin, wherein the botulinum toxin is a serotype A;
a surfactant;
about 5 mg to about 250 mg of sucrose or trehalose for each about 100 units of the botulinum toxin; and
a buffer sufficient to maintain a pH of from about 5.5 to about 6.5 upon reconstitution with sterile normal saline or water;
wherein the composition is suitable for intramuscular or subcutaneous injection following reconstitution with sterile normal saline or water,
wherein the composition is animal protein free, and
wherein the composition retains at least about 75% of the theoretical maximum potency of the botulinum toxin following storage as a powder for three months at room temperature.

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, comprising about 100 units to about 200 units of the botulinum toxin.

### Claim 18 (depends on 16)

The pharmaceutical composition of claim 16, wherein the buffer is a citrate or a phosphate buffer.

### Claim 19 (depends on 16)

The pharmaceutical composition of claim 16, wherein the surfactant is poloxamer 188.

### Claim 20 (depends on 16)

The pharmaceutical composition of claim 16, wherein the room temperature is from about 20° C.
